Kenvue Inc
Company Profile
Business description
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Contact
199 Grandview Road
SkillmanNJ08558
USAT: +1 908 874-1200
Sector
Consumer Defensive
Stock type
Defensive
Industry
Household & Personal Products
Fiscal Year End
31 December 2024
Employees
22,000
Kenvue Inc News & Analysis
stocks
9 best US dividend aristocrats to buy now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.10 | 48.60 | 0.57% |
| CAC 40 | 7,319.35 | 36.66 | 0.50% |
| DAX 40 | 19,894.21 | 45.44 | 0.23% |
| Dow JONES (US) | 42,965.91 | 359.89 | -0.83% |
| FTSE 100 | 8,130.87 | 6.12 | -0.08% |
| HKSE | 20,090.46 | 7.83 | -0.04% |
| NASDAQ | 19,584.71 | 435.65 | -2.18% |
| Nikkei 225 | 40,281.16 | 713.10 | 1.80% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 5,953.84 | 83.75 | -1.39% |
| S&P/ASX 200 | 8,261.80 | 40.90 | 0.50% |
| SSE Composite Index | 3,400.14 | 2.07 | 0.06% |